1. AB0568 BASELINE EUROPEAN PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 3 STUDY OF SAFETY AND EFFICACY OF LENABASUM, A CB2 AGONIST, IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. (2nd June 2020) Authors: Denton, C.; Bloom, B.; Dgetluck, N.; White, B.; Spiera, R. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema. Issue 3 (March 2014) Authors: Aberer, W.; Maurer, M.; Reshef, A.; Longhurst, H.; Kivity, S.; Bygum, A.; Caballero, T.; Bloom, B.; Nair, N.; Malbrán, A. Journal: Allergy Issue: Volume 69:Issue 3(2014:Mar.) Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-0747: Setting defaults in palliative radiation: a value-driven approach to improving care. (May 2017) Authors: Puckett, L.; Lee, L.; Zhang, I.; Zuvic, P.; Gilbo, P.; Potters, L.; Bloom, B. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO-0878 Implementing a dedicated inpatient radiation team with multidisciplinary palliative care rounds. (April 2019) Authors: Mark, D.; Gilbo, P.; Joseph, S.; Goenka, A.; Bloom, B. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗